文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

联合全身炎症免疫指数和预后营养指数作为新辅助化疗局部晚期胃癌的化疗敏感性和预后标志物的回顾性研究。

Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.

机构信息

Research Center and Tumor Research Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.

The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.

出版信息

BMC Cancer. 2024 Aug 15;24(1):1014. doi: 10.1186/s12885-024-12771-z.


DOI:10.1186/s12885-024-12771-z
PMID:39148031
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328362/
Abstract

BACKGROUND: The prognosis nutritional index (PNI) and the systemic inflammatory immunological index (SII) are characteristic indicators of the nutritional state and the systemic inflammatory response, respectively. However, there is an unknown combined effect of these indicators in the clinic. Therefore, the practicality of using the SII-PNI score to predict prognosis and tumor response of locally advanced gastric cancer (LAGC) following chemotherapy was the main focus of this investigation. METHODS: We retrospectively analyzed 181 patients with LAGC who underwent curative resection after neoadjuvant chemotherapy in a prospective study (NCT01516944). We divided these patients into tumour regression grade(TRG) 3 and non-TRG3 groups based on tumor response (AJCC/CAP guidelines). The SII and PNI were assessed and confirmed the cut-off values before treatment. The SII-PNI values varied from 0 to 2, with 2 being the high SII (≥ 471.5) as well as low PNI (≤ 48.6), a high SII or low PNI is represented by a 1 and neither is represented by a 0, respectively. RESULTS: 51 and 130 samples had TRG3 and non-TRG3 tumor responses respectively. Patients with TRG3 had substantially higher SII-PNI scores than those without TRG3 (p < 0.0001). Patients with greater SII-PNI scores had a poorer prognosis (p < 0.0001). The SII-PNI score was found to be an independent predictor of both overall survival (HR = 4.982, 95%CI: 1.890-10.234, p = 0.001) and disease-free survival (HR = 4.763, 95%CI: 1.994-13.903, p = 0.001) in a multivariate analysis. CONCLUSION: The clinical potential and accuracy of low-cost stratification based on SII-PNI score in forecasting tumor response and prognosis in LAGC is satisfactory.

摘要

背景:预后营养指数(PNI)和全身炎症免疫指数(SII)分别是营养状态和全身炎症反应的特征指标。然而,这些指标在临床上的联合作用尚不清楚。因此,本研究主要关注 SII-PNI 评分在预测局部晚期胃癌(LAGC)化疗后预后和肿瘤反应中的实际应用。

方法:我们对 181 例接受新辅助化疗后行根治性切除术的 LAGC 患者进行了前瞻性研究(NCT01516944)。我们根据肿瘤反应(AJCC/CAP 指南)将这些患者分为肿瘤消退分级(TRG)3 组和非 TRG3 组。在治疗前评估 SII 和 PNI,并确定截断值。SII-PNI 值从 0 到 2 变化,2 表示高 SII(≥471.5)和低 PNI(≤48.6),高 SII 或低 PNI 表示为 1,两者均无表示为 0。

结果:51 例和 130 例患者的肿瘤反应分别为 TRG3 和非 TRG3。TRG3 患者的 SII-PNI 评分明显高于非 TRG3 患者(p<0.0001)。SII-PNI 评分较高的患者预后较差(p<0.0001)。多因素分析显示,SII-PNI 评分是总生存(HR=4.982,95%CI:1.890-10.234,p=0.001)和无病生存(HR=4.763,95%CI:1.994-13.903,p=0.001)的独立预测因子。

结论:SII-PNI 评分基于低成本分层在预测 LAGC 肿瘤反应和预后方面具有令人满意的临床潜力和准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/e484935ad179/12885_2024_12771_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/27fe6cb99f98/12885_2024_12771_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/f656a9cf17f0/12885_2024_12771_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/16aa8bb285a5/12885_2024_12771_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/9b06b67e9181/12885_2024_12771_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/e5dcfd7417d5/12885_2024_12771_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/4cd8a98a7296/12885_2024_12771_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/e484935ad179/12885_2024_12771_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/27fe6cb99f98/12885_2024_12771_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/f656a9cf17f0/12885_2024_12771_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/16aa8bb285a5/12885_2024_12771_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/9b06b67e9181/12885_2024_12771_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/e5dcfd7417d5/12885_2024_12771_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/4cd8a98a7296/12885_2024_12771_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdff/11328362/e484935ad179/12885_2024_12771_Fig7_HTML.jpg

相似文献

[1]
Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.

BMC Cancer. 2024-8-15

[2]
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.

BMC Gastroenterol. 2022-3-14

[3]
Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib.

BMC Gastroenterol. 2023-1-23

[4]
Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.

BMC Cancer. 2024-12-24

[5]
Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer.

Front Nutr. 2022-8-15

[6]
Predicting the prognosis of patients with renal cell carcinoma based on the systemic immune inflammation index and prognostic nutritional index.

Sci Rep. 2024-10-23

[7]
Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.

Front Oncol. 2023-4-3

[8]
Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.

J Surg Oncol. 2022-3

[9]
Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study.

Front Oncol. 2022-1-19

[10]
Systemic immunoinflammatory index and prognostic nutrition index for predicting pathologic responses of patients with advanced gastric cancer after neoadjuvant therapy for advanced gastric cancer.

Am J Cancer Res. 2024-8-25

引用本文的文献

[1]
Nutritional status of patients with driver gene mutation-negative non-small cell lung cancer after postoperative adjuvant chemotherapy.

J Thorac Dis. 2025-6-30

[2]
Predicting the prognosis of patients with renal cell carcinoma based on systemic immune inflammatory index and prognostic nutritional index.

Int Urol Nephrol. 2025-5-12

[3]
Large Unstained Cells: A Predictive Biomarker for Recurrence and Survival in Resected Gastric Cancer.

Medicina (Kaunas). 2025-1-24

[4]
Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study.

PeerJ. 2024-12-17

本文引用的文献

[1]
Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.

Pathol Oncol Res. 2022

[2]
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.

BMC Gastroenterol. 2022-3-14

[3]
Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study.

Front Oncol. 2022-1-19

[4]
Systemic Immune-Inflammatory Index Association with Survival in Patients Undergoing Trimodality Therapy for Lung Cancer.

Oncology. 2022

[5]
Associations between Nutritional and Immune Status and Clinicopathologic Factors in Patients with Pancreatic Cancer: A Comprehensive Analysis.

Cancers (Basel). 2021-10-9

[6]
Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.

JAMA Surg. 2022-1-1

[7]
Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.

Br J Radiol. 2021-8-1

[8]
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.

Lancet Oncol. 2021-8

[9]
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.

Cancer Commun (Lond). 2021-8

[10]
Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications.

Int J Mol Sci. 2021-4-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索